Natixis Advisors LLC Purchases 80,070 Shares of Novo Nordisk A/S (NYSE:NVO)

Natixis Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 3,074,876 shares of the company's stock after purchasing an additional 80,070 shares during the period. Novo Nordisk A/S accounts for approximately 0.7% of Natixis Advisors LLC's holdings, making the stock its 19th largest position. Natixis Advisors LLC owned about 0.07% of Novo Nordisk A/S worth $366,125,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of NVO. Price T Rowe Associates Inc. MD raised its holdings in Novo Nordisk A/S by 10.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company's stock valued at $1,102,857,000 after acquiring an additional 823,036 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.4% during the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company's stock worth $607,242,000 after buying an additional 58,935 shares in the last quarter. GQG Partners LLC boosted its position in shares of Novo Nordisk A/S by 654.6% in the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company's stock valued at $466,485,000 after acquiring an additional 3,151,584 shares during the period. Raymond James & Associates grew its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company's stock valued at $419,939,000 after acquiring an additional 36,223 shares in the last quarter. Finally, 1832 Asset Management L.P. increased its position in Novo Nordisk A/S by 7.8% during the first quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company's stock worth $304,697,000 after acquiring an additional 172,003 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVO shares. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $144.50.

Novo Nordisk A/S Price Performance

NYSE:NVO traded down $3.58 during trading hours on Friday, hitting $101.74. The company's stock had a trading volume of 8,076,248 shares, compared to its average volume of 4,457,389. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock has a fifty day simple moving average of $118.58 and a 200-day simple moving average of $129.58. The company has a market capitalization of $456.56 billion, a P/E ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.